Drug Trial Radar · NCT05775159
Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer
Last checked: Nov 19, 2026Latest source record: Aug 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
294
Planned (sponsor's estimate)
Start
Apr 24, 2023
Primary completion
Oct 27, 2026
Study completion Oct 28, 2027
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Mar 20, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
GEMINI-Hepatobiliary study will assess the efficacy, safety and tolerability of novel immunomodulators alone and in combination with other anticancer drugs in participants with specified advanced solid tumors.
Conditions
- Hepatocellular Carcinoma
- Biliary Tract Cancer
Interventions
VolrustomigDrug
CTLA-4/Anti-PD-1 Bispecific Antibody
BevacizumabDrug
15 mg/kg, IV (in the vein) on day 1 of each 21 day cycle. Number of Cycles: until disease progression or unacceptable toxicity develops.
LenvatinibDrug
Daily use per oral (8 mg capsules/day for participants \< 60 kg or 12 mg/day for participants ≥ 60 kg) of 21 day cycle. Number of Cycles: until disease progression or unacceptable toxicity develops.
RilvegostomigDrug
anti- PD-1 and TIGIT bispecific antibody
GemcitabineDrug
1000 mg/m2, IV infusion
CisplatinDrug
25 mg/m2, IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective response rate (ORR)Time frame: Through study completion, an average of 2 years
- The number of participants with adverse events/serious adverse eventsTime frame: Through study completion, an average of 2 years
- Progression free survival (PFS)Time frame: Through study completion, an average of 2 years
Locations
46 sites in 9 countries. Site status is shown where the registry gives one.
Research Site
Birmingham, Alabama
Research Site
Los Angeles, California
Research Site
Orange, California
Research Site
Kansas City, Kansas
Research Site
New York, New York
Research Site
Beijing, China
Research Site
Beijing, China
Research Site
Beijing, China
Research Site
Chengdu, China
Research Site
Chengdu, China
Research Site
Chongqing, China
Research Site
Fuzhou, China
Research Site
Guangzhou, China
Research Site
Guangzhou, China
Research Site
Harbin, China
Research Site
Nanning, China
Research Site
Shanghai, China
Research Site
Hong Kong, Hong Kong
Research Site
Shatin, Hong Kong
Research Site
Florence, Italy
Research Site
Milan, Italy
Research Site
Naples, Italy
Research Site
Rozzano, Italy
Research Site
Chūōku, Japan
Research Site
Kashiwa, Japan
Research Site
Yokohama, Japan
Research Site
Seongnam-si, South Korea
Research Site
Seoul, South Korea
Research Site
Seoul, South Korea
Research Site
Seoul, South Korea
Research Site
Seoul, South Korea
Research Site
Barcelona, Spain
Research Site
Barcelona, Spain
Research Site
Madrid, Spain
Research Site
Madrid, Spain
Research Site
Pamplona, Spain
Research Site
Kaohsiung City, Taiwan
Research Site
Kaohsiung City, Taiwan
Research Site
Taichung, Taiwan
Research Site
Tainan, Taiwan
Showing 40 of 46 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.